Anti-Infliximab (REMICADE) ELISA Assay Kit

$1,190.00

The Anti-Infliximab (REMICADE) ELISA Assay Kit has been especially developed for the qualitative analysis of antibodies to infliximab in serum and plasma samples. The Anti-Infliximab (REMICADE) ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

SKU: INF-QLS-REMI Categories: , ,

Anti-Infliximab (REMICADE) ELISA Assay Kit

The Anti-Infliximab (REMICADE) ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Name: Remicade


Assay Background

Infliximab is a tumor necrosis factor (TN Fa) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. TN Fa isa key pro-inflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signaling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNFa, infliximab disrupts the interaction of TNFa with its receptors and may also cause lysis of cells that produce TN Fa. Infliximab is an IgG1 K monoclonal antibody that binds to soluble and transmembrane forms of TNFa with high affinity to disrupt the pro-inflammatory cascade signaling. Binding of the antibody to TN Fa prevents TN Fa from interacting with its receptors. Infliximab does not neutralize TNFa (lymphotoxin-a), a related cytokine that utilizes the same receptors as TNFa. Blocked actions of TNFa further leads to downregulation of local and systemic pro- inflammatory cytokines (i.e. IL-1, IL-6), reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes), increased levels of nuclear factor-KB inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins. Its inhibitory actions on TN Fa was demonstrated in human fibroblasts, endothelial cells, neutrophils, B and T lymphocytes and epithelial cells. Infliximab also attenuates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes.

Assay Principle

Solid phase enzyme-linked immunosorbent assay {ELISA) based on the sandwich principle. Controls and samples {serum or plasma) are incubated in the microtiter plate coated with the drug infliximab. After incubation, the wells are washed. Then, horse radish peroxidase {HRP) conjugated probe is added and binds to infliximab antibodies captured by the drug infliximab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of infliximab antibodies in the sample or controls. The results can be evaluated with using cut-off value.


Related Products:

Infliximab ELISA Assay Kit
Total Infliximab ELISA Assay

Package Inserts


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations